Shanbrom Technologies, LLC Patent applications |
Patent application number | Title | Published |
20100233672 | GRAPE POLYPHENOLICS FOR PLATELET AND BACTERIAL CONTROL - Special extracts of grape berries and Goji berries can be prepared by exposing fruit juices or preparations to an insoluble binding resin which is then extracted with soluble polyvinylpyrollidone. Grape and Goji extracts made in this way can be used to inhibit or control platelet aggregation. Grape extract has exceptional antibacterial properties and can be used to control oral bacteria and to control MRSA (Methicillin-resistant | 09-16-2010 |
20090123907 | LYSINE CITRATE FOR PLASMA PROTEIN AND DONOR PROTECTION - An improved anticoagulant or additive is based on a higher level of citric acid than is usual (at least about 1.0% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits or kills bacteria such as | 05-14-2009 |
20090117057 | Grape Polyphenolics for Platelet and Bacterial Control - Special extracts of grape berries and Gogi berries can be prepared by exposing fruit juices or preparations to an insoluble binding resin which is then extracted with soluble polyvinylpyrollidone. Grape and Goji extracts made in this way can be used to inhibit or control platelet aggregation. Grape extract has exceptional antibacterial properties and can be used to control oral bacteria and to control MRSA (Methicillin-resistant | 05-07-2009 |
20090018313 | ENHANCED PRODUCTION OF BLOOD CLOTTING FACTORS AND FIBRIN FABRIC - The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and plasma proteins and with the removal of the activated and denatured components thereby improving safety and efficacy of end products. The inventive process is particularly suited to an improved extraction process to yield concentrated clotting factors from single donors or limited pools without use of chromatography. Following extraction the remaining cryoprecipitate can advantageously be formed into a fibrin fabric used in surgeries and in the treatment of wounds. | 01-15-2009 |
20080281081 | Polyvinyl Pyrollidone Cryoprecipitate Extraction of Clotting Factors - Blood collection, processing and transfer leads to the separation of discrete fractions by adding additional citrate (trisodium citrate) to bring the citrate concentration to 10%-15% w/v thereby leading to enhanced yield and purity of cryoprecipitate. The improved cryoprecipitate then yields concentrated clotting factors by an improved extraction process which uses polyvinyl pyrollidone to reduce the extraction of fibrinogen. Following extraction the remaining cryoprecipitate can advantageously be formed into a fibrin fabric used in surgeries and in the treatment of wounds | 11-13-2008 |